In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viragen, Inc.

Latest From Viragen, Inc.

Roche’s Vabysmo Chases Regeneron’s Eylea With New Pivotal Macular Edema Wins

The Swiss major’s new bispecific antibody could challenge Eylea’s standard of care status in another ophthalmic indication, macular edema due to retinal vein occlusion, but the older rival is set to hit back in bigger markets with a high-dose reformulation.

Companies Clinical Trials

Six Pivotal Trial Readouts To Look Out For In Q4

With help from Biomedtracker, Scrip takes a look at six drug candidates expecting pivotal data by the end of the year. The assets span a range of therapeutic areas, from ophthalmology to neurology, and are poised to become market firsts, rivals to dominant products or win important label expansions.

Clinical Trials Companies

High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share

The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.

Ophthalmic Clinical Trials

Serum Scores A Double - HPV Vaccine In India, Novavax Vaccine In US

Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.

Commercial Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Transgenics
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register